Optimum Patient Care (OPC)
This sponsor has funded 3 studies across 3 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 14111 | Planned | Not included in RMP | Impact of Optimum Patient Care’s clinical review service (Impact of OPC) | No | No |
| 29401 | Planned | Not included in RMP | Advancing the Patient Experience in COPD Registry (APEX COPD) | No | No |
| 107087 | Ongoing | Not included in RMP | Understanding high-risk COPD: Analysis of real-world data to investigate characteristics and outcomes in patients with high-risk COPD. (OPRI 2306:... | No | No |
PAS by Risk Management Plan (RMP) requirement
Optimum Patient Care (OPC)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Optimum Patient Care (OPC)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Optimum Patient Care (OPC)
3 Study countries specified are the following:
- Australia
- United Kingdom
- United States